After believing he or she escaped the consequences of asbestos exposure, an Ohio resident could receive a devastating diagnosis decades later. The incubation period for mesothelioma can be up to 50 years, and by the time it is diagnosed, a patient could no longer benefit from surgery or radiation. Under these circumstances, a new device may help.
The Food and Drug Administration recently approved the new device for use in treating malignant pleural mesothelioma. It must be used in conjunction with the two-drug chemotherapy that is standard for this condition when surgery is not possible. The new treatment is said to inhibit further growth of a tumor, interrupt the rapid division of cancerous cells and kill cancer cells.
The device, called the NovoTTF-100L System, consists of transducer arrays, a power supply, connection cables, a generator, a carrying bag, and a battery and battery charger. The patient wears the portable unit no less than 18 hours per day during which he or she receives alternating electrical fields. The patient may take small breaks from wearing the device during that time. Individuals with sensitivity to conductive gels or implanted electronic medical devices should not use the product despite the fact that clinical trials indicate an increased life expectancy for those who used the device.
Ohio residents who suffer from malignant pleural mesothelioma that cannot be treated with surgery or radiation may want to ask their doctors about this new treatment. It may be worthwhile for some patients who can gain precious months with their loved ones that they would not ordinarily have with such a diagnosis. Moreover, it could give a patient time to consult with an attorney experienced in cases involving asbestos-related illnesses in order to pursue much needed benefits.
